T-lymphocytes

CELL-LINE

Drugs acting on this target (56)

Active Pharmaceutical Ingredient	Mechanism Type ▲	Approval Status	API Type	Mechanism of Action
clbs03	Immunity, desensitized	experimental	Cell therapy	T-lymphocytes immunity, desensitized
anti-t-cell antibodies	Immunity, passive	experimental	Biological	T-lymphocytes immunity, passive
cd3/cd28 stimulated t cells	Immunity, passive	experimental	Cell therapy	T-lymphocytes immunity, passive
ex vivo activated immune cells	Immunity, passive	experimental	Cell therapy	T-lymphocytes immunity, passive
immuncell-lc	Immunity, passive	experimental	Cell therapy	T-lymphocytes immunity, passive
wt1-sensitized t cells	Immunity, passive	experimental	Cell therapy	T-lymphocytes immunity, passive
allogeneic cd3+ cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
allogeneic central memory t cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
allogeneic double negative t cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
allogeneic gamma-delta t cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
allogeneic lymphocytes	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
allogeneic multivirus - directed cytotoxic t lymphocytes	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
allogeneic t cell progenitors, cultured ex-vivo	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
allogeneic virus-specific t cell lines	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
alloreactive ctl	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
alpha/6-gag-tcr modified t cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
atir101	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
autologous activated lymphocyte	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
autologous cd34+pbsc, transduced with a lentiviral vector (-889itga2b-bddfviii-wpts(mut6)(vsvg)	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
autologous cd4 t-cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
autologous cd4+ t cells genetically modified with a retroviral vector expressing the mazf endoribonuclease gene	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
autologous cd4+t cells stimulated and expanded ex vivo by a mog peptide modified by the introduction of a thioreductase motif into the flanking residues of the t cell epitope	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
autologous ebv specific cytotoxic t lymphocytes	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
autologous t cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
autologous thytreg	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
base-edited t lymphocyte cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
blinatumomab expanded t-cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
cd4+ t cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
cd4+cd25+cd127lowfoxp3+ t regulatory cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
cytotoxic t cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
dartreg	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
donor th-2 cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
donor-alloantigen-reactive regulatory t cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
DRI cell	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
eagd t-cell	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
engineered autologous t cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
ex vivo cd3/cd28-costimulated vaccine-primed peripheral blood autologous t cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
ex vivo expanded t cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
fluorocalcium phosphosilicate	Supplementation	experimental	Small molecule	T-lymphocytes supplementation
fucosylated regulatory t cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
gamma-delta t cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
mana 312	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
mcpyv tag-specific polyclonal autologous cd8-positive t cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
pd-1 and ace2 knockout t cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
pd-1 knockout t cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
re-activated t cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
rivogenlecleucel	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
senl103	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
silane fluoride	Supplementation	experimental	Small molecule	T-lymphocytes supplementation
t-cell depleted hsv-tk engineering donor lymphocytes	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
t-reg depleted dli	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
th1/tc1 rapa cell	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
th2 cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
th2 rapa cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
zfn modified cd4+ t cells	Supplementation	experimental	Cell therapy	T-lymphocytes supplementation
hsvtk retrovirally-transduced donor t lymphocytes	Tissue restoration	experimental	Cell therapy	T-lymphocytes tissue restoration